INNATE PHARMA : PRELIMINARY PHASE 1/2 EFFICACY DATA OF LIRILUMAB IN COMBINATION WITH OPDIVO (NIVOLUMAB)

Preliminary Phase 1/2 Efficacy Data of Lirilumab in Combination with Opdivo (Nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck to be presented during SITC meeting

MARSEILLE, France, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces the publication of the late-breaking abstract on an interim efficacy analysis from a Phase 1/2 study of the combination of lirilumab and Opdivo (nivolumab) in the cohort of advanced platinum refractory squamous cell carcinoma of the head and neck (SCCHN). The abstract is available on the Society for Immunotherapy of Cancer's (SITC) website.

In the abstract, data reports that among 29 evaluable patients with SCCHN, the objective response rate (ORR), as measured by Response Evaluation Criteria In Solid Tumors (RECIST), was 24 percent (n=7) and the disease control rate (DCR) was 52 percent (n=15). Seventeen percent (n=5) of these evaluable patients had deep responses, with reductions in tumor burden greater than 80 percent. Preliminary efficacy of lirilumab plus nivolumab in patients with advanced platinum-refractory SCCHN suggests clinical benefit with encouraging response rates and potential for deep and durable responses.

Lirilumab is directed against the inhibitory killer-cell immunoglobulin-like receptors (KIRs) expressed predominantly on natural killer (NK) cells, which belong to the innate immune system, while Opdivo blocks the inhibitory function of the PD-1 receptor on T cells.

Detailed data will be presented at a late-breaking oral presentation (Late-Breaking Abstract Session II) at SITC Annual Meeting on November 12 at 11:15 a.m. ET in National Harbor, Maryland, by Rom Leidner, Medical Oncologist, Earle A. Chiles Research Institute, Providence Cancer Center (Portland, OR, U.S.) and lead author of the study.